Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia

Guilherme Augusto Dos Santos, Lev Kats, Pier Paolo Pandolfi, Guilherme Augusto Dos Santos, Lev Kats, Pier Paolo Pandolfi

Abstract

Acute promyelocytic leukemia (APL) is a hematological malignancy driven by a chimeric oncoprotein containing the C terminus of the retinoic acid receptor-a (RARa) fused to an N-terminal partner, most commonly promyelocytic leukemia protein (PML). Mechanistically, PML-RARa acts as a transcriptional repressor of RARa and non-RARa target genes and antagonizes the formation and function of PML nuclear bodies that regulate numerous signaling pathways. The empirical discoveries that PML-RARa-associated APL is sensitive to both all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO), and the subsequent understanding of the mechanisms of action of these drugs, have led to efforts to understand the contribution of molecular events to APL cell differentiation, leukemia-initiating cell (LIC) clearance, and disease eradication in vitro and in vivo. Critically, the mechanistic insights gleaned from these studies have resulted not only in a better understanding of APL itself, but also carry valuable lessons for other malignancies.

Figures

Figure 1.
Figure 1.
Elimination of leukemic blasts and LICs is necessary for definitive cure of APL. LICs posses high self-renewal capability and give rise to leukemic blasts that form the bulk of the disease (middle). Both ATRA and ATO promote remission of disease by targeting leukemic blasts. Pharmacological doses of ATRA predominantly drive differentiation of leukemic blasts, but are unable to efficiently eliminate LICs that can drive disease relapse (right). In contrast, ATO induces both apoptosis and differentiation of leukemic blasts and can also target LICs and is therefore more effective that ATRA as a monotherapy (left). ATRA acts synergistically with ATO and/or CT, and these combination therapies definitively cure APL in the vast majority of cases (dashed arrow).
Figure 2.
Figure 2.
Mechanisms of proteolysis of PML-RARa by ATRA and ATO. ATRA induces degradation of RARa and PML-RARa via the RARa moiety. ATO induces degradation of PML and PML-RARa via the PML moiety.
Figure 3.
Figure 3.
Rationale for using arsenic trioxide ATO to eliminate LICs in CML. CML is driven by the Bcr-Abl oncoprotein that displays aberrant tyrosine kinase signaling. Tyrosine kinase inhibitors (TKI) such as imatinib can block aberrant signaling and prevent the formation of leukemic cells, but they do not eliminate LICs, thus requiring continuous treatment, inevitably resulting in resistance and relapse. ATO may synergize with TKI to eliminate LICs, thereby curing the disease.

References

    1. Ablain J., Nasr R., Bazarbachi A., de Thé H. 2011. The drug-induced degradation of oncoproteins: an unexpected Achilles’ heel of cancer cells? Cancer Discov. 1:117–127 10.1158/-11-0087
    1. Ablain J., Leiva M., Peres L., Fonsart J., Anthony E., de Thé H. 2013. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies. J. Exp. Med. 210:647–653 10.1084/jem.20122337
    1. Alcalay M., Zangrilli D., Pandolfi P.P., Longo L., Mencarelli A., Giacomucci A., Rocchi M., Biondi A., Rambaldi A., Lo-Coco F., et al. 1991. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc. Natl. Acad. Sci. USA. 88:1977–1981 10.1073/pnas.88.5.1977
    1. Arteaga M.F., Mikesch J.H., Qiu J., Christensen J., Helin K., Kogan S.C., Dong S., So C.W. 2013. The histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia. Cancer Cell. 23:376–389 10.1016/j.ccr.2013.02.014
    1. Au W.Y., Chim C.S., Lie A.K., Liang R., Kwong Y.L. 2002. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br. J. Haematol. 117:130–132 10.1046/j.1365-2141.2002.03409.x
    1. Bernardini S., Nuccetelli M., Noguera N.I., Bellincampi L., Lunghi P., Bonati A., Mann K., Miller W.H., Jr, Federici G., Lo-Coco F. 2006. Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4. Ann. Hematol. 85:681–687 10.1007/s00277-006-0139-8
    1. Borrow J., Goddard A.D., Sheer D., Solomon E. 1990. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science. 249:1577–1580 10.1126/science.2218500
    1. Breitman T.R., Collins S.J., Keene B.R. 1981. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood. 57:1000–1004
    1. Brown D., Kogan S., Lagasse E., Weissman I., Alcalay M., Pelicci P.G., Atwater S., Bishop J.M. 1997. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA. 94:2551–2556 10.1073/pnas.94.6.2551
    1. Camacho L.H., Soignet S.L., Chanel S., Ho R., Heller G., Scheinberg D.A., Ellison R., Warrell R.P., Jr 2000. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J. Clin. Oncol. 18:2620–2625
    1. Campana D. 2009. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol. Oncol. Clin. North Am. 23:1083–1098: vii (vii.) 10.1016/j.hoc.2009.07.010
    1. Castaigne S., Chomienne C., Daniel M.T., Ballerini P., Berger R., Fenaux P., Degos L. 1990. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood. 76:1704–1709
    1. Catalano A., Dawson M.A., Somana K., Opat S., Schwarer A., Campbell L.J., Iland H. 2007. The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood. 110:4073–4076 10.1182/blood-2007-06-095554
    1. Chen G.Q., Shi X.G., Tang W., Xiong S.M., Zhu J., Cai X., Han Z.G., Ni J.H., Shi G.Y., Jia P.M., et al. 1997. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 89:3345–3353
    1. Chomienne C., Ballerini P., Balitrand N., Huang M.E., Krawice I., Castaigne S., Fenaux P., Tiollais P., Dejean A., Degos L., et al. 1990. The retinoic acid receptor alpha gene is rearranged in retinoic acid-sensitive promyelocytic leukemias. Leukemia. 4:802–807
    1. Chou W.C., Chen H.Y., Yu S.L., Cheng L., Yang P.C., Dang C.V. 2005. Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 106:304–310 10.1182/blood-2005-01-0241
    1. Choudhry A., DeLoughery T.G. 2012. Bleeding and thrombosis in acute promyelocytic leukemia. Am. J. Hematol. 87:596–603 10.1002/ajh.23158
    1. Côté S., Zhou D., Bianchini A., Nervi C., Gallagher R.E., Miller W.H., Jr 2000. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. Blood. 96:3200–3208
    1. de Thé H., Chen Z. 2010. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat. Rev. Cancer. 10:775–783 10.1038/nrc2943
    1. de Thé H., Chomienne C., Lanotte M., Degos L., Dejean A. 1990. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 347:558–561 10.1038/347558a0
    1. de Thé H., Lavau C., Marchio A., Chomienne C., Degos L., Dejean A. 1991. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 66:675–684 10.1016/0092-8674(91)90113-D
    1. de Thé H., Le Bras M., Lallemand-Breitenbach V. 2012. The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. J. Cell Biol. 198:11–21 10.1083/jcb.201112044
    1. dos Santos G.A., Abreu e Lima R.S., Pestana C.R., Lima A.S., Scheucher P.S., Thomé C.H., Gimenes-Teixeira H.L., Santana-Lemos B.A., Lucena-Araujo A.R., Rodrigues F.P., et al. 2012. (+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo. Leukemia. 26:451–460 10.1038/leu.2011.216
    1. El Hajj H., El-Sabban M., Hasegawa H., Zaatari G., Ablain J., Saab S.T., Janin A., Mahfouz R., Nasr R., Kfoury Y., et al. 2010. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J. Exp. Med. 207:2785–2792 10.1084/jem.20101095
    1. Gaillard E., Bruck N., Brelivet Y., Bour G., Lalevée S., Bauer A., Poch O., Moras D., Rochette-Egly C. 2006. Phosphorylation by PKA potentiates retinoic acid receptor alpha activity by means of increasing interaction with and phosphorylation by cyclin H/cdk7. Proc. Natl. Acad. Sci. USA. 103:9548–9553 10.1073/pnas.0509717103
    1. Ghavamzadeh A., Alimoghaddam K., Rostami S., Ghaffari S.H., Jahani M., Iravani M., Mousavi S.A., Bahar B., Jalili M. 2011. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J. Clin. Oncol. 29:2753–2757 10.1200/JCO.2010.32.2107
    1. Goto E., Tomita A., Hayakawa F., Atsumi A., Kiyoi H., Naoe T. 2011. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood. 118:1600–1609 10.1182/blood-2011-01-329433
    1. Grimwade D., Vyas P., Freeman S. 2010. Assessment of minimal residual disease in acute myeloid leukemia. Curr. Opin. Oncol. 22:656–663 10.1097/CCO.0b013e32833ed831
    1. Grisolano J.L., Wesselschmidt R.L., Pelicci P.G., Ley T.J. 1997. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood. 89:376–387
    1. Guillemin M.C., Raffoux E., Vitoux D., Kogan S., Soilihi H., Lallemand-Breitenbach V., Zhu J., Janin A., Daniel M.T., Gourmel B., et al. 2002. In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J. Exp. Med. 196:1373–1380 10.1084/jem.20021129
    1. Hauser S., Adelmant G., Sarraf P., Wright H.M., Mueller E., Spiegelman B.M. 2000. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J. Biol. Chem. 275:18527–18533 10.1074/jbc.M001297200
    1. He L.Z., Tribioli C., Rivi R., Peruzzi D., Pelicci P.G., Soares V., Cattoretti G., Pandolfi P.P. 1997. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc. Natl. Acad. Sci. USA. 94:5302–5307 10.1073/pnas.94.10.5302
    1. He L.Z., Guidez F., Tribioli C., Peruzzi D., Ruthardt M., Zelent A., Pandolfi P.P. 1998. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat. Genet. 18:126–135 10.1038/ng0298-126
    1. He L.Z., Bhaumik M., Tribioli C., Rego E.M., Ivins S., Zelent A., Pandolfi P.P. 2000. Two critical hits for promyelocytic leukemia. Mol. Cell. 6:1131–1141 10.1016/S1097-2765(00)00111-8
    1. He L.Z., Tolentino T., Grayson P., Zhong S., Warrell R.P., Jr, Rifkind R.A., Marks P.A., Richon V.M., Pandolfi P.P. 2001. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108:1321–1330
    1. Heidel F.H., Bullinger L., Feng Z., Wang Z., Neff T.A., Stein L., Kalaitzidis D., Lane S.W., Armstrong S.A. 2012. Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell. 10:412–424 10.1016/j.stem.2012.02.017
    1. Hillestad L.K. 1957. Acute promyelocytic leukemia. Acta Med. Scand. 159:189–194 10.1111/j.0954-6820.1957.tb00124.x
    1. Hu J., Liu Y.F., Wu C.F., Xu F., Shen Z.X., Zhu Y.M., Li J.M., Tang W., Zhao W.L., Wu W., et al. 2009. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA. 106:3342–3347 10.1073/pnas.0813280106
    1. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., Gu L.J., Wang Z.Y. 1988. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 72:567–572
    1. Ito K., Bernardi R., Morotti A., Matsuoka S., Saglio G., Ikeda Y., Rosenblatt J., Avigan D.E., Teruya-Feldstein J., Pandolfi P.P. 2008. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 453:1072–1078 10.1038/nature07016
    1. Ito K., Carracedo A., Weiss D., Arai F., Ala U., Avigan D.E., Schafer Z.T., Evans R.M., Suda T., Lee C.H., Pandolfi P.P. 2012. A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat. Med. 18:1350–1358 10.1038/nm.2882
    1. Jeanne M., Lallemand-Breitenbach V., Ferhi O., Koken M., Le Bras M., Duffort S., Peres L., Berthier C., Soilihi H., Raught B., de Thé H. 2010. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell. 18:88–98 10.1016/j.ccr.2010.06.003
    1. Jing Y., Wang L., Xia L., Chen G.Q., Chen Z., Miller W.H., Waxman S. 2001. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood. 97:264–269 10.1182/blood.V97.1.264
    1. Kakizuka A., Miller W.H., Jr, Umesono K., Warrell R.P., Jr, Frankel S.R., Murty V.V., Dmitrovsky E., Evans R.M. 1991. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 66:663–674 10.1016/0092-8674(91)90112-C
    1. Kennedy G.A., Marlton P., Cobcroft R., Gill D. 2000. Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah’s Witness with de novo acute promyelocytic leukaemia. Br. J. Haematol. 111:1103–1105 10.1046/j.1365-2141.2000.02480.x
    1. Koken M.H., Daniel M.T., Gianni M., Zelent A., Licht J., Buzyn A., Minard P., Degos L., Varet B., de Thé H. 1999. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene. 18:1113–1118 10.1038/sj.onc.1202414
    1. Kondo T., Mori A., Darmanin S., Hashino S., Tanaka J., Asaka M. 2008. The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia. Haematologica. 93:1414–1416 10.3324/haematol.12854
    1. Kopf E., Plassat J.L., Vivat V., de Thé H., Chambon P., Rochette-Egly C. 2000. Dimerization with retinoid X receptors and phosphorylation modulate the retinoic acid-induced degradation of retinoic acid receptors alpha and gamma through the ubiquitin-proteasome pathway. J. Biol. Chem. 275:33280–33288 10.1074/jbc.M002840200
    1. Koyama T., Hirosawa S., Kawamata N., Tohda S., Aoki N. 1994. All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood. 84:3001–3009
    1. Kwaan H.C., Huyck T. 2010. Thromboembolic and bleeding complications in acute leukemia. Expert Rev Hematol. 3:719–730 10.1586/ehm.10.71
    1. Lagadinou E.D., Sach A., Callahan K., Rossi R.M., Neering S.J., Minhajuddin M., Ashton J.M., Pei S., Grose V., O’Dwyer K.M., et al. 2013. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 12:329–341 10.1016/j.stem.2012.12.013
    1. Lallemand-Breitenbach V., Guillemin M.C., Janin A., Daniel M.T., Degos L., Kogan S.C., Bishop J.M., de Thé H. 1999. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 189:1043–1052 10.1084/jem.189.7.1043
    1. Lallemand-Breitenbach V., Jeanne M., Benhenda S., Nasr R., Lei M., Peres L., Zhou J., Zhu J., Raught B., de Thé H. 2008. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 10:547–555 10.1038/ncb1717
    1. Lallemand-Breitenbach V., Zhu J., Chen Z., de Thé H. 2012. Curing APL through PML/RARA degradation by As2O3. Trends Mol. Med. 18:36–42 10.1016/j.molmed.2011.10.001
    1. Lessard J., Sauvageau G. 2003. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 423:255–260 10.1038/nature01572
    1. Li J., Chen P., Sinogeeva N., Gorospe M., Wersto R.P., Chrest F.J., Barnes J., Liu Y. 2002. Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J. Biol. Chem. 277:49504–49510 10.1074/jbc.M207836200
    1. Licht J.D., Chomienne C., Goy A., Chen A., Scott A.A., Head D.R., Michaux J.L., Wu Y., DeBlasio A., Miller W.H., Jr, et al. 1995. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 85:1083–1094
    1. Lo-Coco F., Avvisati G., Vignetti M., Thiede C., Orlando S.M., Iacobelli S., Ferrara F., Fazi P., Cicconi L., Di Bona E., et al. ; Gruppo Italiano Malattie Ematologiche dell’Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia 2013. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl. J. Med. 369:111–121 10.1056/NEJMoa1300874
    1. Longo L., Pandolfi P.P., Biondi A., Rambaldi A., Mencarelli A., Lo-Coco F., Diverio D., Pegoraro L., Avanzi G., Tabilio A., et al. 1990. Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. J. Exp. Med. 172:1571–1575 10.1084/jem.172.6.1571
    1. Magee J.A., Piskounova E., Morrison S.J. 2012. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 21:283–296 10.1016/j.ccr.2012.03.003
    1. Mandelli F., Diverio D., Avvisati G., Luciano A., Barbui T., Bernasconi C., Broccia G., Cerri R., Falda M., Fioritoni G., et al. 1997. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell’Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 90:1014–1021
    1. Marasca R., Zucchini P., Galimberti S., Leonardi G., Vaccari P., Donelli A., Luppi M., Petrini M., Torelli G. 1999. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia. Haematologica. 84:963–968
    1. Mathews V., George B., Lakshmi K.M., Viswabandya A., Bajel A., Balasubramanian P., Shaji R.V., Srivastava V.M., Srivastava A., Chandy M. 2006. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 107:2627–2632 10.1182/blood-2005-08-3532
    1. Mathews V., George B., Chendamarai E., Lakshmi K.M., Desire S., Balasubramanian P., Viswabandya A., Thirugnanam R., Abraham A., Shaji R.V., et al. 2010. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J. Clin. Oncol. 28:3866–3871 10.1200/JCO.2010.28.5031
    1. Menell J.S., Cesarman G.M., Jacovina A.T., McLaughlin M.A., Lev E.A., Hajjar K.A. 1999. Annexin II and bleeding in acute promyelocytic leukemia. N. Engl. J. Med. 340:994–1004 10.1056/NEJM199904013401303
    1. Mi J.Q., Li J.M., Shen Z.X., Chen S.J., Chen Z. 2012. How to manage acute promyelocytic leukemia. Leukemia. 26:1743–1751 10.1038/leu.2012.57
    1. Morán J.M., Ortiz-Ortiz M.A., Ruiz-Mesa L.M., Fuentes J.M. 2010. Nitric oxide in paraquat-mediated toxicity: A review. J. Biochem. Mol. Toxicol. 24:402–409 10.1002/jbt.20348
    1. Nasr R., Guillemin M.C., Ferhi O., Soilihi H., Peres L., Berthier C., Rousselot P., Robledo-Sarmiento M., Lallemand-Breitenbach V., Gourmel B., et al. 2008. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat. Med. 14:1333–1342 10.1038/nm.1891
    1. Nawaz Z., Lonard D.M., Dennis A.P., Smith C.L., O’Malley B.W. 1999. Proteasome-dependent degradation of the human estrogen receptor. Proc. Natl. Acad. Sci. USA. 96:1858–1862 10.1073/pnas.96.5.1858
    1. O’Hare T., Zabriskie M.S., Eiring A.M., Deininger M.W. 2012. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat. Rev. Cancer. 12:513–526 10.1038/nrc3317
    1. Pandolfi P.P., Grignani F., Alcalay M., Mencarelli A., Biondi A., Lo-Coco F., Grignani F., Pelicci P.G. 1991. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene. 6:1285–1292
    1. Raelson J.V., Nervi C., Rosenauer A., Benedetti L., Monczak Y., Pearson M., Pelicci P.G., Miller W.H., Jr 1996. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood. 88:2826–2832
    1. Redner R.L. 2002. Variations on a theme: the alternate translocations in APL. Leukemia. 16:1927–1932 10.1038/sj.leu.2402720
    1. Rego E.M., He L.Z., Warrell R.P., Jr, Wang Z.G., Pandolfi P.P. 2000. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc. Natl. Acad. Sci. USA. 97:10173–10178 10.1073/pnas.180290497
    1. Rosenauer A., Raelson J.V., Nervi C., Eydoux P., DeBlasio A., Miller W.H., Jr 1996. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Blood. 88:2671–2682
    1. Rowley J.D., Golomb H.M., Dougherty C. 1977. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet. 1:549–550 10.1016/S0140-6736(77)91415-5
    1. Sanz M.A., Lo-Coco F. 2011. Modern approaches to treating acute promyelocytic leukemia. J. Clin. Oncol. 29:495–503 10.1200/JCO.2010.32.1067
    1. Sanz M.A., Montesinos P. 2010. Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb. Res. 125(Suppl 2):S51–S54 10.1016/S0049-3848(10)70013-X
    1. Sanz M.A., Martín G., Rayón C., Esteve J., González M., Díaz-Mediavilla J., Bolufer P., Barragán E., Terol M.J., González J.D., et al. 1999. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood. 94:3015–3021
    1. Sanz M.A., Martín G., González M., León A., Rayón C., Rivas C., Colomer D., Amutio E., Capote F.J., Milone G.A., et al. ; Programa de Estudio y Traitmiento de las Hemopatías Malignas 2004. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 103:1237–1243 10.1182/blood-2003-07-2462
    1. Sanz M.A., Grimwade D., Tallman M.S., Lowenberg B., Fenaux P., Estey E.H., Naoe T., Lengfelder E., Büchner T., Döhner H., et al. 2009. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 113:1875–1891 10.1182/blood-2008-04-150250
    1. Sengupta A., Ficker A.M., Dunn S.K., Madhu M., Cancelas J.A. 2012. Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells. Blood. 119:494–502 10.1182/blood-2011-06-359232
    1. Shao W., Fanelli M., Ferrara F.F., Riccioni R., Rosenauer A., Davison K., Lamph W.W., Waxman S., Pelicci P.G., Lo-Coco F., et al. 1998. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst. 90:124–133 10.1093/jnci/90.2.124
    1. Shen Z.X., Chen G.Q., Ni J.H., Li X.S., Xiong S.M., Qiu Q.Y., Zhu J., Tang W., Sun G.L., Yang K.Q., et al. 1997. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 89:3354–3360
    1. Shen Z.X., Shi Z.Z., Fang J., Gu B.W., Li J.M., Zhu Y.M., Shi J.Y., Zheng P.Z., Yan H., Liu Y.F., et al. 2004. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA. 101:5328–5335 10.1073/pnas.0400053101
    1. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D.A., et al. 1998. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339:1341–1348 10.1056/NEJM199811053391901
    1. Tallman M.S., Altman J.K. 2009. How I treat acute promyelocytic leukemia. Blood. 114:5126–5135 10.1182/blood-2009-07-216457
    1. Tanaka T., Rodríguez de la Concepción M.L., De Luca L.M. 2001. Involvement of all-trans-retinoic acid in the breakdown of retinoic acid receptors alpha and gamma through proteasomes in MCF-7 human breast cancer cells. Biochem. Pharmacol. 61:1347–1355 10.1016/S0006-2952(01)00600-1
    1. Tatham M.H., Geoffroy M.C., Shen L., Plechanovova A., Hattersley N., Jaffray E.G., Palvimo J.J., Hay R.T. 2008. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 10:538–546 10.1038/ncb1716
    1. Tsimberidou A.M., Tirado-Gomez M., Andreeff M., O’Brien S., Kantarjian H., Keating M., Lopez-Berestein G., Estey E. 2006. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk. Lymphoma. 47:1062–1068 10.1080/10428190500463932
    1. Visani G., Piccaluga P.P., Martinelli G., Rossi M., Malagola M., Baccarani M. 2003. Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease. Haematologica. 88:ELT15.
    1. Wang Z.Y., Chen Z. 2008. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 111:2505–2515 10.1182/blood-2007-07-102798
    1. Wang Y., Krivtsov A.V., Sinha A.U., North T.E., Goessling W., Feng Z., Zon L.I., Armstrong S.A. 2010. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 327:1650–1653 10.1126/science.1186624
    1. Warrell R.P., Jr, Frankel S.R., Miller W.H., Jr, Scheinberg D.A., Itri L.M., Hittelman W.N., Vyas R., Andreeff M., Tafuri A., Jakubowski A., et al. 1991. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 324:1385–1393 10.1056/NEJM199105163242002
    1. Warrell R.P., Jr, He L.Z., Richon V., Calleja E., Pandolfi P.P. 1998. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 90:1621–1625 10.1093/jnci/90.21.1621
    1. Won D., Shin S.Y., Park C.J., Jang S., Chi H.S., Lee K.H., Lee J.O., Seo E.J. 2013. OBFC2A/RARA: a novel fusion gene in variant acute promyelocytic leukemia. Blood. 121:1432–1435 10.1182/blood-2012-04-423129
    1. Yamamoto Y., Tsuzuki S., Tsuzuki M., Handa K., Inaguma Y., Emi N. 2010. BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. Blood. 116:4274–4283 10.1182/blood-2010-01-264432
    1. Yilmaz O.H., Valdez R., Theisen B.K., Guo W., Ferguson D.O., Wu H., Morrison S.J. 2006. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 441:475–482 10.1038/nature04703
    1. Zelent A., Guidez F., Melnick A., Waxman S., Licht J.D. 2001. Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene. 20:7186–7203 10.1038/sj.onc.1204766
    1. Zhang J., Grindley J.C., Yin T., Jayasinghe S., He X.C., Ross J.T., Haug J.S., Rupp D., Porter-Westpfahl K.S., Wiedemann L.M., et al. 2006. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature. 441:518–522 10.1038/nature04747
    1. Zhang X.W., Yan X.J., Zhou Z.R., Yang F.F., Wu Z.Y., Sun H.B., Liang W.X., Song A.X., Lallemand-Breitenbach V., Jeanne M., et al. 2010. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science. 328:240–243 10.1126/science.1183424
    1. Zheng X., Seshire A., Rüster B., Bug G., Beissert T., Puccetti E., Hoelzer D., Henschler R., Ruthardt M. 2007. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica. 92:323–331 10.3324/haematol.10541
    1. Zhu J., Gianni M., Kopf E., Honoré N., Chelbi-Alix M., Koken M., Quignon F., Rochette-Egly C., de Thé H. 1999. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc. Natl. Acad. Sci. USA. 96:14807–14812 10.1073/pnas.96.26.14807

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe